Skip to main content

View full-text article in PMC

. 2015 Mar 11;59(4):1942–1949. doi: 10.1128/AAC.04829-14

TABLE 1.

Effects of drug resistance substitutions on EC₅₀s for DTG, RAL, and EVG^a

Genotype	Fold change EC₅₀ (mean ± SEM) for:
Genotype	DTG	RAL	EVG
stHIV-1
WT	1 ± 0.1	1 ± 0.5	1 ± 0.6
E92Q	1.94 ± 0.3	11.5 ± 2	>300 ± 7.6
G118R	6.44 ± 0.1	5.8 ± 0.6	20.1 ± 0.3
E138K	0.74 ± 0.4	0.41 ± 0.4	16.6 ± 0.3
Y143R	2.06 ± 0.1	35.9 ± 0.6	21.6 ± 0.2
S153Y	2.15 ± 0.2	1.59 ± 0.6	22.8 ± 0.4
N155H	0.76 ± 0.3	14.7 ± 0.6	55.8 ± 0.3
R263K	2.5 ± 0.3	0.83 ± 1.1	32.6 ± 0.4
HIV-1
WT	1	1	1
E92Q	1.6^b	3.5^b	>100^c
G118R	8.2^d	1^d	1^d
E138K	0.97^b	1^b	0.93^b
Y143R	1.4^b	16^b	2.3^c
S153Y	2.5^b	1.3^b	2.3^b
N155H	0.99^b	8.4^b	25^b
R263K	2.3^e	1^e	21.8^e

^a

DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; WT, wild type; SEM, standard error of the mean.

^b

Data from Kobayashi et al. (18).

^c

Data from K. Anstett, submitted for publication.

^d

Data from Bar-Magen et al. (15) and unpublished observations.

^e

Data from Mesplède et al. (32).